100 related articles for article (PubMed ID: 27475670)
1. Macroscopic Hematuria After Conventional or Hypofractionated Radiation Therapy: Results From a Prospective Phase 3 Study.
Sanguineti G; Arcidiacono F; Landoni V; Saracino BM; Farneti A; Arcangeli S; Petrongari MG; Gomellini S; Strigari L; Arcangeli G
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):304-312. PubMed ID: 27475670
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
3. Clinical Outcomes of the CHIRP Trial: A Phase II Prospective Randomized Trial of Conventionally Fractionated Versus Moderately Hypofractionated Prostate and Pelvic Nodal Radiation Therapy in Patients With High-Risk Prostate Cancer.
Wang MH; Vos LJ; Yee D; Patel S; Pervez N; Parliament M; Usmani N; Danielson B; Amanie J; Pearcey R; Ghosh S; Field C; Fallone BG; Murtha AD
Pract Radiat Oncol; 2021; 11(5):384-393. PubMed ID: 33705985
[TBL] [Abstract][Full Text] [Related]
4. Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for Prostate Cancer: Do Dose and Overall Treatment Time Matter?
Kountouri M; Zilli T; Rouzaud M; Dubouloz A; Linero D; Escudé L; Jorcano S; Miralbell R
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):272-9. PubMed ID: 26853336
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Patient-Reported Outcomes From a Phase 3 Randomized Prospective Trial of Conventional Versus Hypofractionated Radiation Therapy for Localized Prostate Cancer.
Shaikh T; Li T; Handorf EA; Johnson ME; Wang LS; Hallman MA; Greenberg RE; Price RA; Uzzo RG; Ma C; Chen D; Geynisman DM; Pollack A; Horwitz EM
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):722-731. PubMed ID: 28244407
[TBL] [Abstract][Full Text] [Related]
6. Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial.
Zapatero A; Guerrero A; Maldonado X; Álvarez A; González-San Segundo C; Cabeza Rodriguez MA; Macías V; Pedro Olive A; Casas F; Boladeras A; Martín de Vidales C; Vázquez de la Torre ML; Calvo FA
Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):341-348. PubMed ID: 27598804
[TBL] [Abstract][Full Text] [Related]
7. Hyprofractionated Versus Conventionally Fractionated Radiation Therapy for Patients with Intermediate- or High-Risk, Localized, Prostate Cancer: 7-Year Outcomes From the Randomized, Multicenter, Open-Label, Phase 3 HYPRO Trial.
de Vries KC; Wortel RC; Oomen-de Hoop E; Heemsbergen WD; Pos FJ; Incrocci L
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):108-115. PubMed ID: 31593756
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial comparing hypofractionated and conventionally fractionated three-dimensional conformal external-beam radiotherapy for localized prostate adenocarcinoma: a report on the first-year biochemical response.
Norkus D; Miller A; Plieskiene A; Janulionis E; Valuckas KP
Medicina (Kaunas); 2009; 45(6):469-75. PubMed ID: 19605967
[TBL] [Abstract][Full Text] [Related]
9. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
10. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
11. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
[TBL] [Abstract][Full Text] [Related]
12. Current evidence for moderate and ultra-hypofractionated radiation therapy in prostate cancer: a summary of the results from phase 3 randomised trials.
Lilleby O; Meidahl Petersen P; Daugaard G; Anne Perell K
Scand J Urol; 2023 Jun; 58():21-27. PubMed ID: 37338209
[TBL] [Abstract][Full Text] [Related]
13. Later outcomes and alpha/beta estimate from hypofractionated conformal three-dimensional radiotherapy versus standard fractionation for localized prostate cancer.
Leborgne F; Fowler J; Leborgne JH; Mezzera J
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):1200-7. PubMed ID: 21477933
[TBL] [Abstract][Full Text] [Related]
14. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
15. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
Zelefsky MJ; Fuks Z; Hunt M; Lee HJ; Lombardi D; Ling CC; Reuter VE; Venkatraman ES; Leibel SA
J Urol; 2001 Sep; 166(3):876-81. PubMed ID: 11490237
[TBL] [Abstract][Full Text] [Related]
16. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
[TBL] [Abstract][Full Text] [Related]
17. Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
Lettmaier S; Lotter M; Kreppner S; Strnad A; Fietkau R; Strnad V
Radiother Oncol; 2012 Aug; 104(2):181-6. PubMed ID: 22853851
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
[TBL] [Abstract][Full Text] [Related]
19. Increased radiation dose heterogeneity within the prostate predisposes to urethral strictures in patients receiving moderately hypofractionated prostate radiation therapy.
McDonald AM; Baker CB; Popple RA; Cardan RA; Fiveash JB
Pract Radiat Oncol; 2015; 5(5):338-342. PubMed ID: 25858771
[TBL] [Abstract][Full Text] [Related]
20. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials.
Lehrer EJ; Kishan AU; Yu JB; Trifiletti DM; Showalter TN; Ellis R; Zaorsky NG
Radiother Oncol; 2020 Jul; 148():235-242. PubMed ID: 32505965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
